ARB: Clinical Trials

4 trials of ARB, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown, 1 completed, 1 terminated. 4 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 44Unknown 2, Completed 1, Terminated 1

Follow ARB: new trials by email Literature Review of ARB trials Research Report on ARB

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sacubitril/Valsartan for CKD5 Stage Dialysis Patients
Sacubitril/Valsartan, Irbesartan - CKD5 Stage Dialysis, Heart Failure
Phase 4CompletedRuijin Hospital3302020-08-012023-03-17
Randomized Evaluation of Beta Blocker and ACEI/ARB Treatment in MINOCA Patients - MINOCA-BAT
Beta blocker, ACEI, ARB - Myocardial Infarction With Non-obstructive Coronary Arteries
Phase 4TerminatedUppsala University1982018-12-162023-11-27
Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy
Mycophenolate Mofetil, ACE inhibitor, Corticosteroid - IgA Nephropathy
Phase 4UnknownYonsei University1002016-06-012016-12-05
Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)
ARB, Pentoxifylline, Placebo (for Pentoxifylline) - Chronic Renal Failure
Phase 4UnknownNational Taiwan University Hospital3502010-06-012016-10-14

Conditions studied

Glomerulonephritis, IGA (1)  ·  Heart Failure (1)  ·  Kidney Failure, Chronic (1)  ·  MINOCA (1)  ·  Myocardial Infarction (1)  ·  Renal Insufficiency, Chronic (1)

Sponsors

National Taiwan University Hospital (1)  ·  Ruijin Hospital (1)  ·  Uppsala University (1)  ·  Yonsei University (1)

Countries

Australia (1)  ·  China (1)  ·  New Zealand (1)  ·  Norway (1)  ·  South Korea (1)  ·  Spain (1)  ·  Sweden (1)  ·  Taiwan (1)

Top investigators

Bertil Lindahl, Prof (1)  ·  Yung-Ming Chen, M.D.; PhD (1)

Results publications

PMID 33203618, PMID 42246870